Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 1/20 | 0.57 |
| ▸ | PRKD1 | Q15139 | 9/20 | 0.47 |
| ▸ | TACR3 | P29371 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5526273 | 0.90 | MELK (0.45) | MELKPRKD1TACR3KDM4EFLT3 | |
| SCHEMBL5534704 | 0.90 | MELK (0.47) | MELKPRKD1TACR3MAP4K1KDM4E | |
| SCHEMBL5531729 | 0.81 | MELK (0.57) | MELKPRKD1MAP4K1AURKAKDR | |
| SCHEMBL12077119 | 0.76 | FLT3 (0.52) | MELKPRKD1AURKAKDRFLT3 | |
| SCHEMBL27823075 | 0.73 | MELK (0.52) | MELKPRKD1CHEK1AURKAKDR | |
| SCHEMBL5531735 | 0.72 | AOC3 (0.48) | MELKPRKD1CHEK1MAP4K1KDR | |
| SCHEMBL27802503 | 0.71 | MELK (0.60) | MELKPRKD1MAP4K1AURKAKDR | |
| SCHEMBL7000736 | 0.71 | MELK (0.54) | MELKPRKD1TACR3MAP4K1AURKA | |
| SCHEMBL27802563 | 0.70 | PRKD1 (0.67) | MELKPRKD1AURKAKDRFLT3 | |
| SCHEMBL1081001 | 0.70 | PRKD1 (0.73) | MELKPRKD1CHEK1MAP4K1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710038-B2 | Pyrazole kinase modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | MAP3K1, MAP3K3, MAP3K5 | MELK 235/4885PRKD1 104/4885TACR3 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.